These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 8828742

  • 1. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ, Zöller B, Fenner T, Lichtenberg G, van Lunzen J, Albrecht H, Thiele HG, Greten H.
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug 10; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Aug 10; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J.
    AIDS Rev; 2002 Aug 10; 4(2):83-92. PubMed ID: 12152521
    [Abstract] [Full Text] [Related]

  • 13. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M, Nogués Biau A, Falguera Sacrest M, Puig Ganau T, Lecha N, Rubio Rivas C.
    An Med Interna; 2000 Oct 10; 17(10):533-7. PubMed ID: 11109648
    [Abstract] [Full Text] [Related]

  • 14. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G, Italian MASTER Cohort.
    J Antimicrob Chemother; 2007 Jun 10; 59(6):1141-7. PubMed ID: 17434879
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct 01; 12(14):F151-60. PubMed ID: 9792371
    [Abstract] [Full Text] [Related]

  • 16. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 15; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 18. Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.
    Vogel M, Lichterfeld M, Kaufmann DE, Mui SK, Altfeld M, Voigt E, Ahlenstiel G, Kupfer B, Walker B, Spengler U, Rockstroh JK.
    Eur J Med Res; 2006 Jul 31; 11(7):273-8. PubMed ID: 16899420
    [Abstract] [Full Text] [Related]

  • 19. Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.
    Anderson AM, Kosinski AS, Bartlett JA.
    Antivir Ther; 2007 Jul 31; 12(7):1041-8. PubMed ID: 18018762
    [Abstract] [Full Text] [Related]

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 31; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.